Changes in the Board of Directors at Ypsomed

Ad hoc announcement pursuant to Art. 53 LR

Burgdorf – Ypsomed (SIX: YPSN) announces changes to the Board of Directors. The founder and Chairman of the Board of Directors of the Ypsomed Group Dr. h.c. Willy Michel will not stand for re-election as Chairman and member of the Board of Directors at the upcoming Annual General Meeting on 29 June 2022. The Board of Directors proposes to the Annual General Meeting 2022 to elect the current member of the Board of Directors, Gilbert Achermann as new Chairman. Simon Michel will be nominated for election as a new member of the Board of Directors.

Lees meer...

Ypsomed partners with CamDiab Ltd to drive on smartphone based adaptive automated insulin delivery (AID)

Burgdorf – Ypsomed partners with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid closed-loop approach. During the first half of 2022, this easy-to-use loop solution will be launched for the mylife YpsoPump system, starting in selected major countries in Europe and followed by other territories in the course of the year. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX Android mobile application and are enabled to algorithm-based insulin delivery support including bolus from the personal smartphone.

Lees meer...

Sébastien Delarive to become new Senior Vice President Diabetes Care
Sébastien Delarive to become new Senior Vice President Diabetes Care.

Ypsomed focuses on growth and strengthens its business units

Press Releases Ypsomed Group

Burgdorf – With the aim of focusing on changing customer needs, Ypsomed is stepwise optimizing the organisation of the business units and the Management Board.

Lees meer...